Sputum Colour as a Marker for Bacteria in Acute Exacerbations of COPD: Protocol for a Systematic Review and Meta-Analysis.

Ruan Spies (✉ ruanspies21@gmail.com)  
University of Cape Town  https://orcid.org/0000-0002-1584-9141

Matthew Wade Potter  
Port Elizabeth Hospital Complex

Ruan Hollamby  
Helen Joseph Hospital

Stefan van der Walt  
General Justice Gizenga Mpanza Regional Hospital

Ameer Hohlfeld  
Cochrane South Africa

Eleanor Ochodo  
Stellenbosch University Faculty of Medicine and Health Sciences

Richard Nellis van Zyl-Smit  
University of Cape Town Faculty of Health Sciences

Protocol

Keywords: COPD, Acute exacerbation of COPD, sputum colour, sputum purulence, chronic bronchitis, emphysema

Posted Date: January 20th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-148329/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Systematic Reviews on July 27th, 2021. See the published version at https://doi.org/10.1186/s13643-021-01767-6.
Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a major cause of years of life lost globally. Acute exacerbations of COPD (AECOPD) drive disease progression, reduce quality of life and are a source of mortality in COPD. Approximately 50% of AECOPD are due to bacterial infections. Diagnosing bacterial infection as the aetiology of AECOPD however remains challenging as investigations are limited by practicality, accuracy and expense. Clinicians have traditionally used sputum colour as a marker of bacterial infection in AECOPD, despite the lack of high-quality evidence for this practice. The aim of this systematic review and meta-analysis is to determine the diagnostic accuracy of sputum colour in the diagnosis of bacterial causes of AECOPD.

Methods

Articles will be searched for in electronic databases (PubMed, Scopus, Web of Science, Africa-Wide, CINAHL and Health Source Nursing Academy) and we will conduct a review of citation indexes and the grey literature. Two reviewers will independently conduct study selection, against pre-defined eligibility criteria, data extraction and quality assessment of included articles using the QUADAS-2 tool. We will perform a meta-analysis using a bivariate logistic regression model with random effects. We will explore heterogeneity through the visual examination of the forest plots of sensitivities and specificities and through the inclusion of possible sources of heterogeneity as covariates in a meta-regression model if sufficient studies are included in the analysis. We also perform a sensitivity analysis to explore the effect of study quality on our findings. The results of this review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement and will be submitted for peer-review and publication.

Discussion

The findings of this review will assist clinicians in diagnosing the aetiology of AECOPD and may have important implications for decision making in resource-limited settings, as well as for antimicrobial stewardship.

Systematic review registration: PROSPERO CRD42019141498

Background

Chronic obstructive pulmonary disease (COPD) is the 7th leading cause of years of life lost globally. The disease is a major source of chronic morbidity and is associated with a significant economic and social burden. Acute exacerbations of COPD (AECOPD) are defined by the acute worsening of respiratory symptoms which require additional therapy.
AECOPD increase rates of rehospitalization, drive disease progression, reduce quality of life and are a source of mortality in COPD.\textsuperscript{[6-8]} It is estimated that 50-70\% of exacerbations may be due to respiratory infections, including bacteria, atypical bacteria and respiratory viruses.\textsuperscript{[9]} The use of antibiotics in AECOPD is controversial.\textsuperscript{[10-11]} Current treatment guidelines recommend antibiotic therapy in patients with moderate to severe AECOPD with three cardinal symptoms (increase in dyspnoea, sputum volume and sputum purulence) or two cardinal symptoms including sputum purulence; or in patients who require mechanical ventilation\textsuperscript{[5]}. No definition of purulence is provided, and this assessment is thus left to the clinician's judgement. A Cochrane review on antibiotic use in AECOPD reported inconsistent treatment effects across different grades of exacerbation severity.\textsuperscript{[12]} Clinicians thus need to carefully consider the benefits of antibiotic therapy in AECOPD against the potential harms, including the emergent public health crisis of antibiotic resistance.\textsuperscript{[13]}

Current investigations for the diagnosis of bacterial infections in AECOPD are cumbersome and lack sensitivity.\textsuperscript{[5]} Sputum cultures require at least two days incubation while microbiological analysis is often limited by technical issues related to sample adequacy.\textsuperscript{[5]} In areas remote from laboratory services, access to sputum analysis may not be possible and delays to sample processing and reporting may testing unfeasible. Furthermore, the respiratory tracts of individuals with COPD may be colonized by potentially pathogenic microorganisms, and the detection of bacteria in sputum may not reliably discriminate infection from colonization.\textsuperscript{[14]} Biomarkers also have limited value. C-reactive protein is not specific and although procalcitonin may be more specific for bacterial infections, its use is limited by expense, limited availability and current lack of strong evidence to recommend its use.\textsuperscript{[5,15]} The analysis of sputum colour is a clinical sign traditionally utilized by clinicians in the assessment of AECOPD. Purulent sputum, typically defined as green, yellow or brown coloured sputum, may result from the increased recruitment of neutrophils into the sputum, with colouring resulting from the green myeloperoxidase present in these cells.\textsuperscript{[16]} This is thought to represent an acute inflammatory response to bacterial infection.\textsuperscript{[16]} The landmark study by Anthonisen demonstrated a significant treatment effect when antibiotics where used in patient with AECOPD and purulent sputum.\textsuperscript{[17]} However, this study did not investigate the sputum bacteriology of the participants and there is subsequently a lack of high-quality evidence supporting the use of sputum colour as a diagnostic marker in AECOPD.\textsuperscript{[12]}

Sputum colour analysis may be an attractive option for clinicians, should it prove to be an accurate marker of bacterial infection. It is a rapid assessment that can be made immediately at the bedside, allowing for early initiation of appropriate antibiotic therapy. Furthermore, sputum colour assessment tools have been developed which may help improve the consistency and accuracy of such measurement.\textsuperscript{[18]}

There are, to the best of our knowledge, no existing systematic reviews of this subject. It is unlikely that sputum colour alone will be useful in determining the presence of bacterial infection in AECOPD. However, it will benefit clinicians to better understand the sensitivity and specificity of sputum colour assessment so that it may be used appropriately in context with other clinical, laboratory and radiological findings. In
resource limited settings, where access to radiology, biomarkers and microbiology may be unavailable, understanding the sensitivity and specificity of sputum colour as a marker for bacteria in AECOPD may improve the accuracy of clinical diagnosis, minimize patient waiting times due to sample transport and reduce subsequent loss to follow up.

**Objectives**

The primary objective of this systematic review is to evaluate the diagnostic accuracy of sputum colour as a marker for the presence of bacteria in the sputum of adults with AECOPD.

**Methods**

This study will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Diagnostic Test Accuracy studies extension (PRISMA-DTA) standards in reporting the findings of this review. This content of this protocol has been written in accordance with the Preferred Reporting Items for Systematic Review and Meta-analyses Protocols (PRISMA-P) guidelines. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 27 September 2019 with registration number CRD42019141498.

**Criteria for considering studies for this review**

A study will only be deemed eligible for review if it fulfils the inclusion criteria and if it does not fulfil any of the exclusion criteria as demonstrated in Table 1.

**Types of studies**

We will include prospective, retrospective, cross-sectional and randomized-controlled trial studies which report the accuracy of sputum colour in identifying the presence of bacteria in AECOPD. We will not restrict studies by language or publication date. We will only include studies in which the data required to populate 2 X 2 tables are reported, can be reconstructed from reported summary estimates or can be provided by the authors of primary diagnostic studies.

Case reports, case series, diagnostic case-control studies with healthy controls and studies presenting insufficient data for the construction of a 2 X 2 table will be excluded from this review.

**Participants**

We will include studies of participants diagnosed with COPD that have been complicated by acute exacerbation of any severity. We will include studies involving participants of any age greater than or including 18 and any gender. In studies where participants are not limited to adults with COPD, only data pertaining to this patient groups will be reviewed.
We will exclude studies involving participants with stable COPD or other respiratory diseases including pneumonia, bronchiectasis, asthma, acute bronchitis and interstitial lung disease.

**Index tests**

Our index test is sputum colour as a marker for the presence of bacteria in the sputum of adults with AECOPD. We will include studies in which sputum colour has been macroscopically assessed by a professional health care worker or reported by patients. Professional health care workers will for this purpose include doctors, nurses, physiotherapists, respiratory therapists and laboratory based medical scientists. An index test will be considered positive if sputum colour is assessed as “purulent”, “green”, “yellow” and “brown”. An index test will be considered negative if sputum colour is assessed as “mucoid”, “colourless”, “grey” or “white”.

**Target conditions**

AECOPD secondary to bacterial infection is the target condition. This is defined as the acute worsening of respiratory symptoms, in a patient with COPD, which requires further therapy and is likely due to bacterial aetiology.[5]

**Reference standards**

The reference standard is the detection of potentially pathogenic bacteria on bacterial culture of an adequate sputum sample. A sputum sample will be regarded as adequate if it satisfies either the Murray-Washington or Bartlett microscopic assessment criteria. The Murray-Washington criteria define an adequate sputum specimen by the presence of less than 10 squamous epithelial cells per low-power field. [21] The Bartlett criteria derives a score based on the number of neutrophils per low-power field, the presence of mucous strands and the number of squamous epithelial cells per low-power field.[22] A score of 1, 2 or 3 defines and adequate sample.[22]

**Search methods for identification of studies**

**Electronic searches**

We will search the following databases for studies to be included in this systematic review: PubMed, Scopus, Web of Science, Africa-Wide, CINAHL, EMBASE and Health Source Nursing Academy. We will use a combination of Medical Subject Heading (MeSH) terms and free text terms on these platforms. All databases will be searched from inception until present. Table 2 demonstrates our main search strategy for our PubMed search which will be modified for the other databases.

**Searching other resources**

We will review citation indexes and the references lists of the studies identified through the electronic search for additional articles not found during the initial search. We will also conduct a grey literature
search to include conference papers, theses and other unpublished papers (Global Index Medicus, OpenGrey, OpenUCT and OpenDoor).

**Data collection and analysis**

The screening process and study selection will be completed in accordance with the guidelines published in the *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy*.[23]

**Selection of studies**

We will use Rayyan QCRI to assist with the screening of titles and abstracts.[24] Two primary reviewers will independently screen all titles identified by the search strategy. The reviewers will complete a standardised coding sheet (Google Forms) indicating whether a study has met the inclusion criteria or the reason a study has been excluded. Duplicated studies will be removed. The more recent publication with the most complete dataset will be included in the event that duplicate publications for the same data are reported.

The reviewers will select studies from the search strategy in two phases:

**Phase 1: Screening of titles and abstracts**

The primary reviewers will evaluate all titles and abstracts from the search strategy against the predetermined inclusion criteria. The full text of a study will be reviewed if it is not apparent from the title and abstract whether a study has met the inclusion criteria, or if both primary reviewers do not exclude the study.

**Phase 2: Screening of full-text studies**

The full text of all potentially eligible studies will be reviewed. A third reviewer will adjudicate any discrepancies between the primary reviewers. The reasons for the exclusion of studies will be documented and presented in a table of excluded studies.

**Data extraction and management**

Two primary reviewers will develop a data extraction form using Google Forms and will independently extract data from all studies fulfilling the eligibility criteria. The data extraction form will be piloted on at least three potentially eligible studies. A third reviewer will adjudicate any discrepancies between the primary reviewers. The following data will be extracted from the included studies:

- Study characteristics: authors, year of publication, geographical region of study conduct, study design, sample size, clinical setting, index test, reference standard and funding source.
- Participant characteristics: Age, gender, disease and exacerbation severity.
Outcomes measures: values of diagnostic 2 x 2 table(s) (number of true positive (a), false positive (b), false negative (c), and true negative (d)) that cross-classified the disease status (as determined by the reference test) and the index test's outcome for each index test evaluated in the included studies) and number of inconclusive results.

We will contact the relevant authors of primary diagnostic studies in the event of missing data.

Assessment of methodological quality

Two investigators will independently evaluate the risk of bias for each article reviewed. Any disagreement will be resolved by a third reviewer. Findings will be reported in accordance with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.[25]

QUADAS-2 is the redesigned and improved version of the Quality Assessment of Diagnostic Accuracy Studies list (QUADAS). It comprises four domains: patient selection, index test, reference standard, and flow and timing. Risk of bias is assessed for each domain, and for the first three domains, a statement on concerns regarding applicability is given. Each key domain has a set of signalling questions to help judge the risk of bias and concerns regarding applicability. Signalling questions are answered as 'yes', 'no', or 'unclear'. Risk of bias is rated as 'low risk of bias', 'high risk of bias', or 'unclear risk of bias'. Concerns regarding applicability are rated as 'low', 'high' or 'unclear'. In Appendix 3 we provide the precise criteria, tailored for this review, with which we expect to assess risk of bias and applicability.

Statistical analysis and data synthesis

Statistical analysis and data synthesis will be completed in accordance with the guidelines published in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.[26]

Our analysis will be conducted at the level of the sample and not at the level of the participant. For example, if a participant in a study produces more than one sputum sample, each sample will be regarded as an independent index test. We will plot the identified sensitivities and specificities for each index test on Forest plots using RevMan.[27] This will allow for visual examination of variation in test accuracy across studies. We will aim to use values reported in the diagnostic 2 X 2 for each included study. If these data are unavailable, we will attempt to reconstruct these values from reported summary measures. Studies with incomplete or inconclusive index test results will be excluded from statistical analysis but will still be summarized in the descriptive analysis. The results of the index test will be dichotomous; “Positive” or “Negative” based on colour of the sputum. Meta-analysis using a bivariate logistic regression model with random effects will be conducted around this common threshold (Positive/Negative) using the xtmelogit function in Stata V.14.2 (Stata Corp, College Station, Texas, USA). This will estimate pooled sensitivity and specificity (with 95% confidence intervals).

Investigations of heterogeneity
We will explore heterogeneity through the visual examination of the forest plots of sensitivities and specificities and through the inclusion of possible sources of heterogeneity as covariates in a meta-regression model if sufficient studies are included in the analysis. We will investigate the following sources of heterogeneity:

- Study setting, that is, outpatient versus inpatient.
- Antibiotic uses, that is, if patients were exposed to antibiotics within 4 weeks of participation in the study; “Yes” if patients were antibiotic exposed and “No” if patients were not antibiotic exposed,
- Source of index test, that is, if sputum colour was assessed by a healthcare professional or patient reported; “Yes” if sputum colour was assessed by a healthcare profession and “No” if sputum colour was patient reported.

**Sensitivity analyses**

We will conduct sensitivity analyses to explore the influence of study quality on our findings, drawing primarily on our assessment of study bias using the QUADAS-2 tool. We will first explore the effect of excluding studies in which the index test or reference standard domains are judged as having a high risk of bias or unclear risk of bias as these are considered the most relevant sources of bias. We will then explore the effect of excluding studies in which two or more domains of the QUADAD-2 are judged as having a high risk of bias or unclear risk of bias. We will also use sensitivity analyses to explore the effect of potentially influential studies, such as studies with accuracy estimates markedly different from the rest of the included studies.

**Assessment of reporting bias**

We will not undertake any formal assessment of reporting bias in our review due to current uncertainty about how to assess reporting bias in reviews of diagnostic test accuracy, particularly in the presence of significant heterogeneity.[26]

**Discussion**

This systematic review and meta-analysis will synthesize the evidence on sputum colour as a marker for bacteria in the sputum of adults with AECOPD from the existing literature. The findings of this review may be of interest to clinicians, particularly in resource-limited settings, who may not have access to biochemical, radiological and microbiological special investigations. Furthermore, the findings of this review may have implication for antibiotic stewardship in AECOPD.

**Abbreviations**

COPD: Chronic obstructive pulmonary disease

AECOPD: Acute exacerbation of chronic obstructive pulmonary disease
Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Competing interests

The authors declare that they have no competing interests

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Author contributions

RS, MP, SvdW, and RH conceived of the review and drafted the protocol. MP undertook a scoping search and developed the search strategy. RS, MWP, SvdW and RH will be involved in data acquisition, data analysis and the interpretation of the results. AH and EO provided methodological advice. AH and RVZS supervised the research. All authors have reviewed the manuscript and have given their approval for publication.

Acknowledgements

We wish to thank Ms Mary Shelton from the University of Cape Town Health Sciences Library for her input in developing this protocol.

References

1. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1736-88.

2. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-45.
3. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002;165(5):704-7.

4. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.

5. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2019 Report. 2019.

6. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. The Lancet. 2007;370(9589):786-96.

7. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-22.

8. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14(2):336-63.

9. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc. 2004;1(2):109-14.

10. Labaki WW, Han MK. Antibiotics for COPD exacerbations. The Lancet Respiratory medicine. 2017;5(6):461-2.

11. Normansell R, Sayer B, Waterson S, Dennett EJ, Del Forno M, Dunleavy A. Antibiotics for exacerbations of asthma. Cochrane Database Syst Rev. 2018;6:CD002741.

12. Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10:CD010257.

13. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13.

14. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2011;52 Suppl 4:S290-5.

15. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017;26(143).

16. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638-45.

17. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.

18. Murray MP, Pentland JL, Turnbull K, MacQuarrie S, Hill AT. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. European Respiratory Journal. 2009;34(2):361-4.

19. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, and the P-DTAG, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-96.
20. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.

21. Murray PR & Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. 1975. Mayo Clinic Proceedings 50, 339–344.

22. Bartlett RC. Medical Microbiology: Quality Cost and Clinical Relevance. 1997. Wiley, New York.

23. de Vet HCW EA, Riphagen II, Aertgeerts B, Pewsner D. Chapter 7: Searching for studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. 0.4 ed: The Cochrane Collaboration; 2008.

24. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.

25. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-36.

26. Macaskill P GC, Deeks J, Harbord R, Takwoingi Y. Chapter 10: Analysing and Presenting Results. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. 1.0 ed: The Cochrane Collaboration; 2010.

27. Cochrane. Review Manager (RevMan) [Computer program]. In: Centre TNC, editor. 5.3 ed. Copenhagen: The Cochrane Collaboration; 2014.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Appendices.docx
- PrismaPChecklist.docx